levated levels of LDL cholesterol are an important risk factor for coronary atherosclerosis and cardiovascular morbidity. 1 However, oxidized LDL is shown to possess more atherogenic properties than native LDL. 2 Actually, several lines of evidence have indicated that oxidatively modified LDL plays a key role in atherogenesis. 3, 4 In oxidized LDL particles, the content of lyso-PC, a polar phospholipid, is found to be dramatically increased. 3, 4 Actually, Parthasarathy and coworkers 5 have demonstrated that as much as 40% of the phosphatidylcholine of LDL is converted to lyso-PC during oxidized modification. In addition, the concentration of lyso-PC is shown to be increased in atherosclerotic arterial lesions in animals fed an atherosclerotic diet. 6 On the other hand, the migration of coronary artery medial SMCs into the intima is proposed to be an initial process of intimal thickening in coronary atherosclerotic lesions. 7, 8 Here, we show for the first time that lyso-PC, not phosphatidylcholine, potently induces migration of human coronary artery SMCs and that this lyso-PC-induced migration can be further induced by a potent mitogen, PDGF-BB, and a vasoconstrictive and growth-promoting peptide, ET-1.
Recently, Chai and coworkers 9 demonstrated that the mechanism of enhanced DNA synthesis by oxidized LDL and lyso-PC at least in part involves an autocrine or paracrine action of release of endogenous bFGF. Therefore, we examined whether this lyso-PC-induced SMC migration is caused by the release of endogenous bFGF.
Finally, we show the interaction of lyso-PC and AM, a novel endothelium-derived vasorelaxant peptide, 10 or vitamin E, a potent antioxidant, on the migration of human coronary artery SMCs.
(palmitoyl), phosphatidylcholine (dipalmitoyl), lysophosphatidylinositol (palmitoyl), lysophosphatidylserine, and BSA were purchased from Sigma Chemical Co. Type I, II, III, or V collagen was purchased from Koken Inc. Flasks and multiwell plates were purchased from Becton Dickinson Co. The cAMP assay kit was purchased from Yamasa Shoyu Co, Ltd. Diff-Quick staining solution was purchased from Green-cross Corp. Forskolin was provided as a gift by Nihon Kayaku Co, Ltd. ET A antagonist, BQ-123, was provided as a gift from New Drug Discovery Research Laboratories, Tsukuba Research Institute, Banyu Pharmaceutical. Neutralizing antibody to bFGF (mouse monoclonal IgG1K) and human bFGF (recombinant) were purchased from Upstate Biotechnology, Inc. Neutralizing antibody to TGF-␤ 1 (rabbit polyclonal antibody) was purchased from Santa Cruz Biotechnology, Inc.
Culture of Human Coronary Artery SMCs
Human coronary artery SMCs were cultured in SmBM containing human epidermal growth factor (0.5 ng/mL), human FGF (2 ng/mL), insulin (5 g/mL), 5% FCS, 50 g/mL gentamicin sulfate, and 50 g/mL amphotericin-B. Cells were identified as SMCs according to their morphological and growth characteristics. 11, 12 Cultures were maintained at 37°C with atmospheric air and 5% CO 2 . Cells were subcultured after treatment with 0.25% trypsin and 0.02% EDTA. Subconfluent SMCs between the fourth and eighth passages were used for the experiments.
Migration Assay
Migration of SMCs was assayed by a modification of the Boyden's chamber method using microchemotaxis chambers (Neuro Probe Inc) and polycarbonate filters (Nucleopore Corp), as previously reported. 11, 12 In all experiments, collagen-coated filters were used. Briefly, the membranes were treated with 0.5N acetic acid and then incubated for 48 to 72 hours at 25°C in a collagen solution (100 g/mL type I collagen in 0.5N acetic acid). They were then air-dried. 11, 12 Type I collagen was used to coat the filters in the chemotaxis chambers, because the chemotactic effect of lyso-PC was greater when type I collagen was used as a substrate than when type II, type III, or type V collagen was used (type IϾtype IIIϾtype VϾtype II).
Cultured SMCs were trypsinized and suspended at a concentration of Ϸ5.0ϫ10
5 cells/mL in SmBM. The cell number was counted with an electronic cell counter (model ZB1, Coulter Electronics). A volume of 200 L of SMC suspension was placed in the upper chamber, and 40 L of medium (0.4% BSA containing 10 Ϫ7 , 5ϫ10 Ϫ7 , 10 Ϫ6 , 5ϫ10 Ϫ6 , 10 Ϫ5 , 5ϫ10
Ϫ5
, 10 Ϫ4 , or 5ϫ10 Ϫ4 mol/L lyso-PC) was placed in the lower chamber. The chamber was incubated at 37°C under 5% CO 2 in air for 6 hours.
Migration activity is calculated as the mean number of migrated cells observed in four high-power fields, as previously reported.
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Four different wells were studied at the same day on the same cell preparation. This procedure was performed in four independent experiments.
In addition, we examined the effects of lysophospholipids structurally similar to lyso-PC, such as phosphatidylcholine, lysophosphatidylinositol, and lysophosphatidylserine on human coronary artery SMC migration.
In experiments to determine the effect of endogenous bFGF or TGF-␤ 1 on lyso-PC-induced SMC migration, two concentrations (1 and 10 g/mL) of neutralizing antibodies to bFGF and TGF-␤ 1 were added to the upper chamber 30 minutes before the addition of lyso-PC to the lower chamber. Neutralizing antibody to bFGF used here reacts with bovine, human, rat, and mouse bFGF and does not cross-react with bovine acidic FGF. The neutralizing antibody to TGF-␤ 1 used here reacts with mouse, rat, and human TGF-␤ 1 and does not cross-react with either TGF-␤ 2 or TGF-␤ 3 .
Effects of PDGF-BB or ET-1 on lyso-PC-induced SMC migration were also examined. Two concentrations of PDGF-BB (0.5 and 2 ng/mL) or ET-1 (10 Ϫ8 and 10 Ϫ7 mol/L) were added to the lower chamber with 5ϫ10
Ϫ6 mol/L lyso-PC. In an experiment to determine the effect of the ET A receptor antagonist BQ-123 on ET-1-induced migration, BQ-123 and ET-1 were added to the lower chamber with lyso-PC.
In experiments to determine the effects of AM or vitamin E on lyso-PC-induced SMC migration, various concentrations (10 Ϫ9 , 10
Ϫ8
, 10 Ϫ7 , and 10 Ϫ6 mol/L) of human AM or 5ϫ10 Ϫ5 mol/L vitamin E were added to the lower chamber in addition to lyso-PC.
In separate experiments to determine the effects of 8-bromocAMP and forskolin on lyso-PC-induced SMC migration, these cAMP-elevating agents were added to the lower chamber in addition to 5ϫ10
Ϫ5 mol/L lyso-PC.
bFGF Measurement
Human coronary artery SMCs were cultured in 35-mm culture dishes, treated with various concentrations of lyso-PC for 6 hours, and then harvested by first rinsing the cultures in Dulbecco's PBS and then overlaying them with 0.2 mL of Dulbecco's PBS containing 2ϫ10
Ϫ3 mol/L PMSF, as previously reported. 13 After cells were disrupted by three cycles of freezing and thawing followed by sonication for 1 minute, the homogenate was centrifuged at 25 000g for 30 minutes. The supernatant was stored at Ϫ80°C until bFGF quantification was performed with a solid-phase ELISA (Quantikine FGF Basic Immunoassay Kit; R&D Systems, Inc). The average recovery rate of bFGF in cell culture medium was 89%. The minimal detectable dose of bFGF was 1 pg/mL. The interassay variation was 8.7%, and the intra-assay variation was 4.6%.
cAMP Measurement
After preincubation, the cell monolayers were washed twice with PBS and then stimulated for 30 minutes with different concentrations of human AM dissolved in SmBM that contained 5ϫ10 Ϫ4 mol/L IBMX. cAMP levels were determined by radioimmunoassay done with the cAMP assay kit, as previously described.
14,15

Calculations and Analysis
The statistical significance of differences in the results was evaluated with an unpaired ANOVA, and P values were calculated by Scheffé's method. 16 All values were expressed as meanϮSD. Figure 1 shows concentration-dependent effects of lyso-PC (10
Results
Effect of Lyso-PC on SMC Migration
Ϫ7
, 5ϫ10 Ϫ7 , 10
Ϫ6
, 5ϫ10
, 10
Ϫ5
, and 5ϫ10 Ϫ5 mol/L) on SMC migration for 6 hours of incubation. Lyso-PC significantly induced migration in a concentration-dependent manner between 10 Ϫ6 and 5ϫ10 Ϫ5 mol/L. By contrast, the migration-stimulatory effects of the higher range of concentrations (10 Ϫ4 and 5ϫ10 Ϫ4 mol/L) of lyso-PC were clearly weak or none ( Figure 1 ).
Micrographs of human coronary artery SMCs taken after a 6-hour migration period clearly show that lyso-PC, not
Selected Abbreviations and Acronyms
AM ϭ adrenomedullin bFGF ϭ basic fibroblast growth factor ET-1 ϭ endothelin-1 ET A ϭ endothelin A-type receptor FGF ϭ fibroblast growth factor IBMX ϭ 3-isobutyl-1-methylxanthine lyso-PC ϭ lysophosphatidylcholine PDGF ϭ platelet-derived growth factor SmBM ϭ smooth muscle cell basal medium SMC ϭ smooth muscle cell TGF-␤ 1 ϭ transforming growth factor-␤ 1 phosphatidylcholine, induced migration in a concentrationdependent manner and without causing apparent morphological injury (Figure 2) . Table 1 shows the effects of other lysophospholipids structurally similar to lyso-PC on SMC migration. When these phospholipids were tested at two comparable concentrations, phosphatidylcholine was without significant activity, and lysophosphatidylinositol and lysophosphatidylserine appear to be much less effective than lyso-PC.
Effects of Neutralizing Antibody to bFGF on Lyso-PC-Induced SMC Migration
To clarify the role of endogenous bFGF in lyso-PC-induced SMC migration, cells were treated with antibody that neutralize bFGF. The results of these experiments are shown in Figure 3 . bFGF slightly but significantly stimulates SMC migration in a concentration-dependent manner ( Figure 3A ).
The addition of neutralizing antibody to bFGF to the upper chamber clearly abolished bFGF-induced SMC migration ( Figure 3A ). The addition of 1 g/mL of neutralizing antibody to bFGF to the upper chamber significantly inhibited lyso-PC-induced migration. When 10 g/mL of antibody was added, the effect was even greater ( Figure 3B ). By contrast, neither 1 g/mL nor 10 g/mL of neutralizing antibody to TGF-␤ 1 to the upper chamber affected lyso-PCinduced migration ( Figure 3B ).
Furthermore, we examined the effect of lyso-PC on bFGF production in cultured human coronary artery SMCs. Lyso-PC significantly increased bFGF production in a concentration-dependent manner between 10 Ϫ6 and 5ϫ10
Ϫ5 mol/L (Figure 4). bFGF concentration caused by 5ϫ10
Ϫ5 mol/L were Ϸ9-fold greater than nonstimulated controls. These results suggest that lyso-PC induces SMC migration at least in part through release of endogenous bFGF.
To further clarify the mechanism by which lyso-PC induces human coronary artery SMC migration, we examined the ability of vitamin E, a potent antioxidant, to inhibit lyso-PC-induced chemotaxis. Vitamin E (5ϫ10 Ϫ5 mol/L) significantly inhibited SMC migration induced by 5ϫ10 Ϫ5 mol/L lyso-PC, whereas vitamin E could not inhibit the nonstimulated and bFGF-induced SMC migration ( Figure 5 ). This suggested that the vitamin E-inhibitable step in the lyso-PC-induced migration was before stimulation by bFGF. Figure 6 shows the effects of PDGF-BB and ET-1 on lyso-PC-induced SMC migration. Lyso-PC-induced migration was significantly enhanced by PDGF-BB. Lyso-PCinduced migration was also enhanced by ET-1. It is of note that ET-1 alone cannot induce SMC migration at the concentrations used in this study ( Figure 6B ). Table 2 shows the effect of the ET A receptor antagonist BQ-123 on the enhancement by ET-1 of lyso-PC-induced migration. BQ-123 clearly inhibited the enhancement by ET-1. This indicates that the enhancement by ET-1 of lyso-PC-induced migration is probably mediated through ET A receptors. By contrast, BQ-123 had no significant effect on lyso-PC-induced migration in the absence of ET-1. Figure 7A shows effects of various concentrations (10
Effects of PDGF-BB and ET-1 on Lyso-PC-Induced SMC Migration
Effect of AM on Lyso-PC-Induced SMC Migration
Ϫ8 , 10
Ϫ7
, and 10
Ϫ5 mol/L lyso-PC-induced SMC migration. Human AM significantly inhibited 5ϫ10
Ϫ6 mol/L lyso-PC-induced migration at concentrations of 10 Ϫ7 and 10 Ϫ6 mol/L. Human AM also inhibited 5ϫ10
Ϫ5 mol/L lyso-PC-induced migration in a concentration-dependent manner between 10 Ϫ8 and 10
Ϫ6
mol/L. The effects of AM on cellular cAMP levels in cells treated with 5ϫ10
Ϫ6 or 5ϫ10 Ϫ5 mol/L lyso-PC are shown in Figure  7B . In parallel with the inhibition by AM of lyso-PC-induced SMC migration, cellular cAMP increased after treatment with AM ( Figure 7A and 7B) .
Effects of 8-Bromo-cAMP and Forskolin on Lyso-PC-Induced SMC Migration
To elucidate whether the inhibitory effect of AM on lyso-PC-induced SMC migration is causally linked to the increase in cellular cAMP, we examined the effect of 8-bromo-cAMP, a cAMP analogue, on lyso-PC (5ϫ10 Ϫ5 mol/L)-induced SMC migration. Inhibition of lyso-PC-induced SMC migration by AM could be reproduced by this analogue at concentrations of 10 Ϫ6 and 10 Ϫ4 mol/L ( Figure 8A) . Furthermore, the effect of forskolin, an activator of adenylate cyclase, on lyso-PC (5ϫ10 Ϫ5 mol/L)-induced SMC migration was examined. The addition of forskolin also reduced lyso-PC-induced SMC migration at concentrations of 10 Ϫ7 and 10 Ϫ5 mol/L ( Figure 8B ).
Discussion
In the present study, we show that lyso-PC, a prominent component of oxidized LDL, 3, 5 induces migration of human coronary artery SMCs. To the best of our knowledge, this is the first demonstration concerning the relationship between lyso-PC and SMC migration. This may support the finding shown by Autio and coworkers 17 and subsequently by our group 12 that oxidized LDL stimulates the migration of cultured rat or human SMCs, because phosphatidylcholine of LDL is found to be converted to lyso-PC during oxidized modification. 5 Furthermore, both lyso-PC and oxidized LDL are shown to stimulate SMC proliferation. 9, 18 Several lines of evidence suggest that oxidized LDL 19 and its major phospholipid component, lyso-PC, are present in the intima. Therefore, these observations raise the hypothesis that the conversion of phosphatidylcholine into lyso-PC in the intima may render it chemotactic for medial SMCs, thus contributing to plaque formation and atherogenesis in the coronary artery.
The specific mechanisms of action of lyso-PC as a chemotactic factor for human coronary artery SMCs remains to be established, but the present findings at least allow us to say something about the possibilities. bFGF was a weak chemoattractant for human coronary artery SMCs and neutralizing antibody to bFGF-inhibited lyso-PC-induced migration of human coronary artery SMCs. Actually, lyso-PC increased bFGF production in these cells. These results raise the possibility that lyso-PC stimulates human coronary artery SMC migration at least in part through release of bFGF, which is similar to the mechanism involved in stimulation of SMC proliferation by lyso-PC. 9 Furthermore, we showed that vitamin E significantly inhibited lyso-PC-induced SMC migration but could not inhibit the bFGF-induced SMC migration. It is therefore likely that the vitamin E-inhibitable step in the lyso-PC-induced SMC migration is before stimulation by bFGF.
Next, we showed that lyso-PC-induced migration could be enhanced by a potent mitogen, PDGF-BB, and the endothelium-derived vasoconstrictive and growth-promoting peptide ET-1. It is of note that ET-1 significantly enhanced lyso-PCinduced migration even though ET-1 alone had no effects on SMC migration, which means the synergism of ET-1 with lyso-PC. Actually, a low concentration of exogenous ET-1 is found to potentiate the vasoconstrictive or mitogenic action of norepinephrine, 20 serotonin, 21 or PDGF. 22 In addition, ET-induced enhancement of SMC migration was clearly inhibited by the ET A receptor antagonist BQ-123. It is therefore likely that this naturally occurring phospholipid may function in combination with PDGF or ET-1 (possibly mediated by ET A receptors) and may contribute to the intimal thickening in coronary atherosclerotic lesions. 23, 24 Conversely, phosphatidylcholine was without significant activity, and lysophosphatidylinositol and lysophosphatidylserine were much less effective than lyso-PC. However, the precise structural specificity of lyso-PC that has such an effect on SMC migration remains to be clarified at this time.
Then, we showed that human AM strongly inhibits lyso-PC-induced migration of human coronary artery SMCs in a concentration-dependent manner. Actually, 5ϫ10
Ϫ5 mol/L lyso-PC-induced SMC migration was significantly inhibited by human AM at concentrations of 10 Ϫ8 to 10 Ϫ6 mol/L. Although human AM (1-52) is the major circulating form of AM, the normal plasma concentrations (Ϸ10 Ϫ11 to 10 Ϫ10 mol/L) are much lower than those of synthetic human AM that inhibited SMC migration in our study. 25, 26 However, local levels of AM in coronary artery tissues may be much higher than plasma concentrations of AM, because it has been demonstrated that a considerable amount of AM is synthesized in and secreted from vascular endothelial cells. 27 Taking the matter into account, our results suggest that AM, by acting locally as a paracrine agent, inhibits the migration of human coronary artery SMCs. Recently, we showed that AM had a modest antiproliferative effect in cultured rat aortic SMCs. 28 Consequently, these findings may raise the possibility that human AM in local vascular tissues antagonizes the development of intimal thickening during the process of coronary atherosclerosis. However, this experiment was done on cultured SMCs. Therefore, any extrapolation from the present experiment on cultured SMCs to in vivo conditions should be carefully performed.
Finally, we have shown that the inhibitory effect of AM on lyso-PC-induced SMC migration is causally linked to the increase in the cellular cAMP. Actually, human AM increased cAMP levels, and this effect paralleled the migrationinhibitory effect of AM. The cAMP-elevating agents 8-bromo-cAMP and forskolin significantly inhibited lyso-PC-induced migration. These results suggest that AM inhibits lyso-PC-induced migration, at least in part, through a cAMP-dependent process.
In conclusion, our results indicate that lyso-PC, a polar phospholipid that accumulates in oxidized LDL and in atherosclerotic arterial wall, 3, 4 can induce migration of human coronary artery SMCs, possibly in combination with PDGF or ET-1, and that this lyso-PC-induced SMC migration is at least in part caused by the release of endogenous bFGF. The conversion of phosphatidylcholine of LDL into lyso-PC during oxidized modification in atherosclerotic arterial wall may contribute to coronary atherogenesis, especially to the initial step of this disorder. Therefore, interventions that prevent this conversion in vivo may be predicted to act to reduce coronary artery medial SMCs into the intima in various pathophysiological settings. Furthermore, our results indicate that AM, a novel endothelium-derived relaxing factor, and vitamin E, an antioxidant, inhibit lyso-PCinduced human coronary artery SMC migration. However, further studies will be necessary to clarify the exact cellular mechanisms responsible for cellular actions of lyso-PC and the interaction of this phospholipid and other vasoactive substances.
